Karolinska Development Future Growth

Future criteria checks 0/6

Karolinska Development is forecast to grow earnings and revenue by 5.8% and 1.8% per annum respectively while EPS is expected to grow by 6.2% per annum.

Key information

5.8%

Earnings growth rate

6.2%

EPS growth rate

Pharmaceuticals earnings growth	19.7%
Revenue growth rate	1.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	18 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0P3C - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2	-24	-25	-25	1
12/31/2025	2	-23	-22	-22	1
12/31/2024	2	-24	-23	-23	1
9/30/2024	2	-29	-26	-26	N/A
6/30/2024	2	-6	-24	-24	N/A
3/31/2024	2	34	-22	-22	N/A
12/31/2023	2	5	-25	-25	N/A
9/30/2023	2	17	-26	-26	N/A
6/30/2023	2	-41	-27	-27	N/A
3/31/2023	2	-87	-27	-27	N/A
12/31/2022	2	-88	-33	-33	N/A
9/30/2022	2	-118	-31	-31	N/A
6/30/2022	2	-72	10	10	N/A
3/31/2022	2	166	10	10	N/A
12/31/2021	2	171	17	17	N/A
9/30/2021	2	276	47	47	N/A
6/30/2021	2	108	2	2	N/A
3/31/2021	2	-106	-6	-6	N/A
12/31/2020	3	-207	-33	-33	N/A
9/30/2020	3	35	-19	-19	N/A
6/30/2020	3	190	-41	-41	N/A
3/31/2020	4	195	-36	-36	N/A
12/31/2019	3	303	-7	-7	N/A
9/30/2019	4	-11	-6	-6	N/A
6/30/2019	4	8	18	18	N/A
3/31/2019	3	32	19	19	N/A
12/31/2018	3	31	13	13	N/A
9/30/2018	3	48	-60	-60	N/A
6/30/2018	3	238	N/A	-56	N/A
3/31/2018	3	185	N/A	-49	N/A
12/31/2017	2	180	N/A	-31	N/A
9/30/2017	5	125	N/A	-6	N/A
6/30/2017	5	-87	N/A	3	N/A
3/31/2017	5	-142	N/A	6	N/A
12/31/2016	5	-217	N/A	-9	N/A
9/30/2016	2	-315	N/A	-32	N/A
6/30/2016	2	-325	N/A	-95	N/A
3/31/2016	3	-904	N/A	-122	N/A
12/31/2015	3	-1,055	N/A	-325	N/A
9/30/2015	4	-980	N/A	-375	N/A
6/30/2015	5	-1,072	N/A	-342	N/A
3/31/2015	5	-608	N/A	-306	N/A
12/31/2014	5	-371	N/A	-108	N/A
9/30/2014	4	-424	N/A	-57	N/A
6/30/2014	5	-396	N/A	-124	N/A
3/31/2014	5	-169	N/A	-54	N/A
12/31/2013	5	-157	N/A	-71	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0P3C is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0P3C is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0P3C is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0P3C's revenue (1.8% per year) is forecast to grow slower than the UK market (3.6% per year).

High Growth Revenue: 0P3C's revenue (1.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0P3C's Return on Equity is forecast to be high in 3 years time

Karolinska Development Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

First quarter 2023 earnings released

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Second quarter 2022 earnings released

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Investor sentiment deteriorated over the past week

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Less than half of directors are independent

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies